Comparative Pharmacology
Head-to-head clinical analysis: MPI DMSA KIDNEY REAGENT versus YTTERBIUM YB 169 DTPA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MPI DMSA KIDNEY REAGENT versus YTTERBIUM YB 169 DTPA.
MPI DMSA KIDNEY REAGENT vs YTTERBIUM YB 169 DTPA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
DMSA (dimercaptosuccinic acid) labeled with technetium-99m binds to renal cortex, particularly proximal tubular cells, allowing scintigraphic imaging of functional renal parenchyma. Uptake correlates with renal blood flow and tubular function.
Ytterbium Yb 169 DTPA is a radiopharmaceutical that emits gamma radiation. After administration, it distributes in the extracellular fluid and is cleared by glomerular filtration. Its mechanism of action is based on physical decay emission of photons for imaging, with no pharmacological effect.
Adults: 74-185 MBq (2-5 mCi) intravenously, single dose for renal imaging.
No standard therapeutic dosing; used as a diagnostic radiopharmaceutical. Typical adult activity: 37-111 MBq (1-3 mCi) intravenous injection for cisternography or CSF shunt evaluation.
None Documented
None Documented
Initial whole-body half-life of dimer captosuccinic acid (DMSA) is 1.1 hours; terminal elimination half-life for cortical retention is 56 days, reflecting prolonged renal tubular uptake.
Terminal: 25-50 days (effective half-life due to physical decay of Yb-169); clinical context: imaging agent for cisternography, half-life reflects biological clearance with physical decay (T1/2 physical: 32 days)
Renal: ~50% excreted unchanged in urine within 24 hours; remaining fraction retained in renal tubular cells with gradual release over weeks.
Renal: >90% unchanged; biliary/fecal: <10%
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical